US equities
|
MU
$1,035.84
▼-4.79%
NVDA
$230.48
▼-2.94%
SNDK
$1,609.46
▼-4.90%
AMD
$620.68
▼-3.90%
INTC
$107.08
▼-5.34%
AAPL
$340.42
▲+1.11%
META
$720.89
▼-0.06%
SPCX
$160.57
▼-4.19%
MU
$1,035.84
▼-4.79%
NVDA
$230.48
▼-2.94%
SNDK
$1,609.46
▼-4.90%
AMD
$620.68
▼-3.90%
INTC
$107.08
▼-5.34%
AAPL
$340.42
▲+1.11%
META
$720.89
▼-0.06%
SPCX
$160.57
▼-4.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Alpha Tau Medical Ltd. - Warrant
(NQ:
DRTSW
)
3.560
-0.360 (-9.18%)
Delayed Quote
Updated: 3:59 PM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alpha Tau Medical Ltd. - Warrant
< Previous
1
2
Next >
Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
August 31, 2026
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's
July 21, 2026
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
July 15, 2026
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel
June 23, 2026
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control
June 11, 2026
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
June 03, 2026
From
Alpha Tau Medical Ltd.; Tolmar Inc.
Via
GlobeNewswire
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
June 01, 2026
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET
May 11, 2026
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
May 08, 2026
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab
May 05, 2026
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026
May 04, 2026
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies
April 27, 2026
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
April 23, 2026
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
April 23, 2026
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau to Present at Sidoti March Virtual Small Cap Conference
March 16, 2026
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
February 24, 2026
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
January 06, 2026
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
January 05, 2026
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
December 09, 2025
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
December 04, 2025
Pancreatic cancer multi-center clinical trial in U.S. is underway; patient recruitment expected to be completed by the end of Q1 2026
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
December 02, 2025
- FDA approval marks Alpha Tau’s fifth simultaneous active U.S. IDE as the Company expands Alpha DaRT’s reach into recurrent prostate cancer -
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
October 21, 2025
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
September 02, 2025
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
April 28, 2025
Investment comes at a pivotal moment for Alpha Tau, which is experiencing remarkable growth on multiple fronts, with four active U.S. trial approvals, expansion into multiple internal organ...
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
April 02, 2025
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
February 24, 2025
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease
February 03, 2025
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
January 27, 2025
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
December 18, 2024
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
December 17, 2024
From
Alpha Tau Medical Ltd.
Via
GlobeNewswire
< Previous
1
2
Next >
